HydraMed logo

HydraMed Review

6.5
★★★☆☆3.3/5
Website is offline and is not taking patients

HydraMed is no longer available as we reviewed it, so this page is kept for reference.

HydraMed: Website is offline and is not taking patients. We're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.

See our top-rated GLP-1 providers →
Compare top-rated alternatives ↓

HydraMed was a telehealth platform that sold compounded semaglutide and tirzepatide, plus a wider peptide menu and mobile IV services, in about a dozen states. Its website stopped working in mid-2026 and the address now shows a parked-domain page, so there is no way to sign up, refill or check prices.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Website offlineNot taking patients

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

Vetted alternatives to HydraMed

7.7/ 10
Partner

Ro

Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

★★★★☆3.9/5

Editorial score · methodology

$149/mosemaglutide
+ required membership
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Ro review →
8.3/ 10
Partner

Collective

Best for: the lowest flat medication price if you can absorb an annual membership fee

★★★★☆4.2/5

Editorial score · methodology

$59/mosemaglutide
+ required membership
$69/motirzepatide
+ required membership
CompoundedSemaglutideTirzepatide
Get StartedRead full Collective review →
8.3/ 10
Partner

CoreAge Rx

Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

★★★★☆4.2/5

Editorial score · methodology

$79/mosemaglutide
“starting at” price
$129/motirzepatide
“starting at” price
CompoundedSemaglutideTirzepatideNAD+SermorelinLegitScript Verified
Get StartedRead full CoreAge Rx review →
HydraMed logo
3.3 / 5
Our editorial rating

HydraMed at a glance

Type
GLP-1 telehealth provider
Availability
11 states
FDA status
1 FDA warning letter on record; see below

How we scored HydraMed

Each dimension is scored algorithmically from HydraMed’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.

Value25%

6.6/10

HydraMed no longer sells GLP-1 treatment, so no current price applies.

Effectiveness25%

6.0/10

HydraMed's offering is not built around the GLP-1 molecules with the strongest weight-loss trial evidence, so weigh the clinical support carefully.

User Experience15%

7.4/10

Online intake and platform experience; 2 platform features disclosed.

Trust & Safety15%

6.3/10

Key details fully confirmed by our editors; an FDA warning letter is on file (see flag above).

Accessibility10%

7.0/10

HydraMed is available in 11 states. Confirm yours is covered.

Support10%

6.4/10

HydraMed provides standard clinician follow-up; no extended coaching or community program is disclosed.

6scored dimensions
671providers compared

Each checked against the provider’s own site.

Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →

How we verified this HydraMed review

Last checked August 2026
  • Confirmed availability in 11 states
  • Checked the FDA warning-letter database for enforcement actions

Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: high.

What we checked

FDA warning-letter register
An active letter is on file for this provider; see below

What we like

  • Review page kept live so former patients get a straight answer

Watch-outs

  • Website is offline, so there is no way to sign up or reorder
  • Received an FDA warning letter in June 2026 about the compounded semaglutide and tirzepatide on its website

HydraMed's website is offline and it is not taking patients

If you came here looking for HydraMed's compounded semaglutide and tirzepatide program, there is nothing left to sign up for. HydraMed's website started returning a server error page in mid-2026, and the address now shows a parked-domain placeholder with no HydraMed content at all: no prices, no intake and no way to reorder.

When it was running, HydraMed sold compounded GLP-1s bundled with the consult, supplies and shipping, alongside a wider peptide menu and mobile IV services, in about a dozen states. HydraMed has published no closure notice and no new address, so we treat it as closed until it comes back with a working site.

What to do if you were a patient

Talk with a prescriber before your current supply runs out. A GLP-1 dose should be continued or adjusted on clinical advice, not interrupted because a provider went offline, and restarting at a high dose after a gap can be unsafe. If your medication label names a pharmacy, keep that information handy, because the dispensing pharmacy is a separate business from the platform that arranged your visits.

Before you move your care, note that in June 2026 the FDA sent HydraMed a warning letter about the compounded semaglutide and tirzepatide offered on its website. Our FDA warning letter tracker lists it alongside letters sent to other telehealth sellers.

Where to look instead

The alternatives listed on this page are all currently operating and carry current prices. You can also start from our semaglutide provider rankings and compare what each provider includes as well as what it charges, using the factors in our scoring methodology.

Bottom line

HydraMed is no longer reachable online and is not taking patients. We keep this page up so people searching for HydraMed get a clear answer rather than a dead link. It is excluded from our rankings and carries no outbound link.

The Bottom Line

HydraMed is no longer available as we reviewed it, so this page is kept for reference.

Score: 6.5/10Best for: former HydraMed patients looking for a current GLP-1 provider

HydraMed might not be your best fit if…

We rank editorially, so here’s where a different provider we track may serve you better.

  • If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider altRX.
  • If you want built-in coaching and behavior-change support, consider Ro.
  • If you live outside its coverage area and need nationwide access, consider CoreAge Rx.

Frequently Asked Questions

Not online. HydraMed's website returned a server error page from at least June 2026, and the address now shows a parked-domain placeholder with no HydraMed content. HydraMed has published no closure notice or new address, so there is no working way to start or continue a program.
Talk with a prescriber before your current supply runs out, so treatment continues without a gap or an unsafe restart dose. If your medication label names a pharmacy, keep that information, because the dispensing pharmacy is a separate business. Then compare current providers on price, medication and state coverage.
People still search for HydraMed, and a clear answer beats a dead link. This page is excluded from every ranking on this site, carries no outbound link to the old service, and points to currently operating alternatives instead.
HydraMed is an operating telehealth provider, but it has an FDA warning letter on file, which this review flags. We scored it 6.5/10 overall. Read the FDA notice before you decide. Talk to a licensed clinician before starting any medication.
The main red flag is an FDA warning letter on file, which this review flags. Read it before starting. We also note: Website is offline, so there is no way to sign up or reorder; Received an FDA warning letter in June 2026 about the compounded semaglutide and tirzepatide on its website.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Regulatory notice

HydraMed received an FDA warning letter dated June 8, 2026

The letter concerns false & misleading claims/misbranded (telehealth). FDA warning letters are public regulatory communications and do not, on their own, constitute a finding of illegal activity. Companies often respond with corrective action.

Read the full letter →

Sources

The primary regulatory filings and peer-reviewed studies cited throughout this HydraMed review:

Sources & methodology (as of November 2026)
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.